A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Combination With CAPOX and Sintilimab in Patients With Advanced, and Unresectable Gastric/Esophagogastric Junction Cancer.

This was an open-label, phase 1/2 study to evaluate safety, tolerability, pharmacokinetics, and antitumor activity of ASKB589 in combination with CAPOX and Sintilimab in first-line treatment of patients with locally advanced, recurrent, or metastatic gastric and esophagogastric junction adenocarcinoma.

开始日期2023-02-10

申办/合作机构

AskGene Pharma, Inc.

[+1]

NCT05638698 / Recruiting临床2期IIT

Phase II Randomized Trial Combining Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer(TESLA)

Researchers want to discover if the new drug "TG01" will work with participants' bodies to help their immune system attack any cancer cells that might still be in the blood stream after surgery for pancreatic cancer.
The researchers will also investigate whether or not "TG01" combined with the other study drug, "Balstilimab", will show even greater efficacy.
TG01 and Balstilimab are both experimental treatments and are not approved by the US Food and Drug Administration (FDA) as treatment in the United States, or elsewhere, for pancreatic cancer or any other type of cancer.
Balstilimab has been studied in other cancers and has shown signs of efficacy. Another drug will be used in this study called "QS-21". It is not intended to treat any disease but is used in this study to improve the action of the study drug TG01.
QS-21 has been approved by the US Food and Drug Administration (FDA) to be mixed with a vaccine used to prevent shingles. It has not been approved to be mixed with the study drug, TG01.
Participants will undergo eligibility screening, weekly visits during treatment when receiving the study drug or study drug combination, two safety follow-up visits, at about 30 and 90 days after the last dose of study treatment, and long term follow up for about 12 months after the last dose of study treatment.

开始日期2022-12-15

申办/合作机构

University of Kansas

[+1]

EUCTR2012-002400-40-ES / Not yet recruiting临床1/2期

A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients with Resected Adenocarcinoma of the Pancreas - Not applicable

开始日期2015-09-30

申办/合作机构-

100 项与阿利考昔相关的临床结果

登录后查看更多信息

100 项与阿利考昔相关的转化医学

登录后查看更多信息

100 项与阿利考昔相关的专利（医药）

登录后查看更多信息

项与阿利考昔相关的文献（医药）

2021-03-31·Genomics & informatics

Identification of potential candidate genes for lip and oral cavity cancer using network analysis

Article

作者: Kue, Chin Siang ; Kumar, Suresh ; Mathavan, Sarmilah

Lip and oral cavity cancer, which can occur in any part of the mouth, is the 11th most common type of cancer worldwide. The major obstacles to patients' survival are the poor prognosis, lack of specific biomarkers, and expensive therapeutic alternatives. This study aimed to identify the main genes and pathways associated with lip and oral cavity carcinoma using network analysis and to analyze its molecular mechanism and prognostic significance further. In this study, 472 genes causing lip and oral cavity carcinoma were retrieved from the DisGeNET database. A protein-protein interaction network was developed for network analysis using the STRING database. VEGFA, IL6, MAPK3, INS, TNF, MAPK8, MMP9, CXCL8, EGF, and PTGS2 were recognized as network hub genes using the maximum clique centrality algorithm available in cytoHubba, and nine potential drug candidates (ranibizumab, siltuximab, sulindac, pomalidomide, dexrazoxane, endostatin, pamidronic acid, cetuximab, and apricoxib) for lip and oral cavity cancer were identified from the DGIdb database. Gene enrichment analysis was also performed to identify the gene ontology categorization of cellular components, biological processes, molecular functions, and biological pathways. The genes identified in this study could furnish a new understanding of the underlying molecular mechanisms of carcinogenesis and provide more reliable biomarkers for early diagnosis, prognostication, and treatment of lip and oral cavity cancer.

2015-12-01·European journal of pharmacology3区 · 医学

Cyclooxygenase-2 inhibitors in lung cancer treatment: Bench to bed

3区 · 医学

Review

作者: Liu, Rui ; Xu, Kang-Ping ; Tan, Gui-Shan

The most common and leading cause of cancer-related death in men is lung cancer. Despite the recent advances in chemotherapy, advanced lung cancer still remains incurable. For this, the understanding of molecular mechanisms involved in lung carcinogenesis is necessary to provide potentially effective therapeutic targets for the treatment of lung cancer, and thus the therapeutic limitations can be overcome. Cyclooxygenase-2 (COX-2) is an important inflammation factor that is reported to be up-regulated in different cancers. A number of COX-2 inhibitors have been developed, but most of them are restricted due to the different risk factors. Currently, the FDA has allowed celecoxib to remain on the market but advised physicians to apply this drug with alternative therapies or to use at a low dosage. Some other COX-2 inhibitors, such as, apricoxib and etoricoxib are under critical investigation currently. Celecoxib is being tested in clinical trials against lung cancer, as a single agent or in combination with other agents. Recent studies have suggested celecoxib as a feasible and clinically active regimen in the treatment of patients with lung cancer. However, more clinical trials are necessary for the better understanding of the role of selective COX-2 inhibitors in the prevention and treatment of lung cancer along with their assessment of toxicity. In this review, we have discussed the mechanism of actions of COX-2 in cancer progression and the therapeutic use of COX-2 inhibitors in the treatment of lung cancer with subsequent clinical studies and future management.

2012-09-15·Clinical cancer research : an official journal of the American Association for Cancer Research1区 · 医学

Apricoxib, a Novel Inhibitor of COX-2, Markedly Improves Standard Therapy Response in Molecularly Defined Models of Pancreatic Cancer

1区 · 医学

Article

作者: Ostapoff, Katherine ; Schwarz, Roderich E. ; Braunfeld, Jordan ; Toombs, Jason E. ; Brekken, Rolf A. ; Carbon, Juliet G. ; Kirane, Amanda ; Burrows, Francis J. ; Zaknoen, Sara

Abstract:

Purpose: COX-2 is expressed highly in pancreatic cancer and implicated in tumor progression. COX-2 inhibition can reduce tumor growth and augment therapy. The precise function of COX-2 in tumors remains poorly understood, but it is implicated in tumor angiogenesis, evasion of apoptosis, and induction of epithelial-to-mesenchymal transition (EMT). Current therapeutic regimens for pancreatic cancer are minimally effective, highlighting the need for novel treatment strategies. Here, we report that apricoxib, a novel COX-2 inhibitor in phase II clinical trials, significantly enhances the efficacy of gemcitabine/erlotinib in preclinical models of pancreatic cancer.Experimental Design: Human pancreatic cell lines were evaluated in vitro and in vivo for response to apricoxib ± standard-of-care therapy (gemcitabine + erlotinib). Tumor tissue underwent posttreatment analysis for cell proliferation, viability, and EMT phenotype. Vascular parameters were also determined.Results: COX-2 inhibition reduced the IC50 of gemcitabine ± erlotinib in six pancreatic cancer cell lines tested in vitro. Furthermore, apricoxib increased the antitumor efficacy of standard combination therapy in several orthotopic xenograft models. In vivo apricoxib combination therapy was only effective at reducing tumor growth and metastasis in tumors with elevated COX-2 activity. In each model examined, treatment with apricoxib resulted in vascular normalization without a decrease in microvessel density and promotion of an epithelial phenotype by tumor cells regardless of basal COX-2 expression.Conclusions: Apricoxib robustly reverses EMT and augments standard therapy without reducing microvessel density and warrants further clinical evaluation in patients with pancreatic cancer. Clin Cancer Res; 18(18); 5031–42. ©2012 AACR.

项与阿利考昔相关的新闻（医药）

2024-03-20

·米内网

苑东拿下大涨130%神经系统药！超30款过评产品亮眼，高端仿制药、1类新药猛攻千亿市场

精彩内容今年以来，苑东生物捷报频传。盐酸纳布啡注射液获批上市，盐酸麻黄碱注射液等3个产品报产在审冲刺首家过评、首仿。近年来苑东生物持续保持高研发投入，2023年，公司有重酒石酸去甲肾上腺素注射液、甲硫酸新斯的明注射液等高端仿制药在国内获批，盐酸纳美芬注射液拿下美国ANDA批文，成为公司首个制剂出海产品。截至目前，苑东生物已有超过30个品种过评，9个为首家过评；此外，有23个品种报产在审，超10个1类新药在研。拿下大涨130%神经系统药，3个新品冲刺首家过评、首仿日前，CDE官网显示，成都苑东生物的盐酸麻黄碱注射液以仿制3类报产在审，获批后视同过评，该产品用于蛛网膜下腔麻醉或硬膜外麻醉引起的低血压症及慢性低血压症。米内网数据显示，盐酸麻黄碱注射液有20家企业拥有生产批文，并无企业过评，且无一致性评价补充申请在审，仅有成都苑东生物报产在审，有望拿下首家过评。来源：米内网项目进度数据库今年以来，苑东生物捷报频传。不久前盐酸纳布啡注射液获批上市，是公司今年首款获批产品，该产品在2022年中国城市公立医院、县级公立医院、城市社区中心及乡镇卫生院（简称中国公立医疗机构）终端销售额超过8亿元，同比增长130.76%，2023年上半年再度增长超过40%。此外，3个产品以新分类报产在审，奥沙西泮片冲刺国产第2家和首家过评，阿帕他胺片则有望拿下首仿和首家过评。重磅新品不断！首个制剂扬帆出海，超30款过评产品亮眼苑东生物2023年国内获批产品来源：米内网中国申报进度（MED）数据库苑东生物2023年有重酒石酸去甲肾上腺素注射液、甲硫酸新斯的明注射液、盐酸阿罗洛尔片等9个高端仿制药在国内获批（按所属企业集团计）；盐酸纳美芬注射液拿下美国ANDA批件，成为公司首个制剂出海产品。此外，公司已立项开发盐酸纳洛酮鼻喷剂（ANDA）、盐酸纳美芬注射液（预充针）（ANDA）、盐酸纳美芬鼻喷剂（505b2）。苑东生物表示，公司将加快鼻喷、预充针等有特色和技术壁垒剂型的开发进度同时，加速制剂国际化战略实施步伐，打造新的增长点。苑东生物通过/视同通过一致性评价品种来源：米内网一致性评价数据库截至目前，苑东生物已有超过30个产品通过/视同通过一致性评价，其中，盐酸尼卡地平注射液、伊班膦酸钠注射液、布洛芬注射液、富马酸比索洛尔片、盐酸纳洛酮注射液等9个为首家过评。值得一提的是，苑东生物有10个产品中标国采，神经系统药物有3个，肌肉-骨骼系统和心脑血管系统药物各有2个，血液和造血系统药物、消化系统及代谢药、全身用抗感染药物各有1个。米内网数据显示，依托考昔片、盐酸法舒地尔注射液等多个产品在2023年上半年中国公立医疗机构终端苑东生物的市场份额均位居前列。高端仿制药、1类新药……猛攻千亿市场近年来，苑东生物持续保持高研发投入，占营收比例20%左右，聚焦重点领域统筹布局生物药、小分子创新药、高端仿制药产品群，打造苑东特色产品管线，形成差异化竞争优势。公司在麻醉镇痛、心血管、抗肿瘤、内分泌和儿童用药五大重点领域布局丰富的在研管线，而麻醉镇痛领域是重点打造的产品管线。苑东生物报产在审产品情况来源：米内网中国申报进度（MED）数据库截至目前，苑东生物有23个产品报产在审，其中16个均在2023年报产，水合氯醛口服液是改良型新药，磷酸芦可替尼片、奥卡西平口服混悬液等有望拿下首仿，注射用盐酸兰地洛尔、阿昔替尼片、水合氯醛灌肠剂等冲刺国产第2家。从治疗大类来看，神经系统药物最多，有7个，其次是心脑血管系统药物和抗肿瘤和免疫调节剂。米内网数据显示，2022年中国公立医疗机构终端神经系统药物市场规模接近1000亿元，抗肿瘤和免疫调节剂和心脑血管系统药物均超过1000亿元，而抗肿瘤和免疫调节剂是TOP1治疗大类。此外，苑东生物有超过10个1类创新药在研，其中自主研发化药1类新药优格列汀片在Ⅲ期临床阶段，进度最快。不久前，有投资者在苑东生物的投资者互动平台问及该产品的临床进展情况，苑东生物表示，公司优格列汀片III期单药临床实验已完成全部受试者临床观察和数据清理，正在进行项目总结。EP-9001A注射液是公司全资子公司成都优洛生物首个自主研发的1类生物药，去年11月发布公告称正开展用于骨转移癌痛的Ib/II临床试验，首例受试者已成功入组给药。该产品特有的非中枢性镇痛机制，能够在强效镇痛同时避免成瘾性产生，并且兼具靶向性强、特异性高的特点，市场前景广阔。资料来源：公司公告、米内网数据库等注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

一致性评价上市批准

2023-10-05

·美通社

美国药监局(FDA)批准创胜集团开展Osemitamab (TST001)作为胃癌或胃食管结合部腺癌患者的一线治疗的全球III期试验

美国新泽西州普林斯顿和中国苏州2023年10月4日 /美通社/ -- 创胜集团(06628.HK)，一家具备生物药品发现、研发、工艺开发和生产全流程整合能力的临床阶段的生物制药公司，宣布美国食品药品监督管理局(FDA)已批准公司开展Osemitamab (TST001)联合纳武利尤单抗及化疗作为HER2阴性、CLDN18.2表达局部晚期或转移性胃癌或胃食管结合部腺癌(G/GEJ)患者一线治疗的TranStar 301全球III期关键性试验。获得该同意标志着Osemitamab (TST001)的全球开发获得重大进展，也是继2023年7月Osemitamab (TST001)的III期关键性试验获中国国家药品监督管理局药品审评中心(CDE)和韩国MFDS批准后的又一个重要里程碑。这一里程碑标志着Osemitamab (TST001)在向全球疗法迈进的过程中取得了重要进展，从而提升了HER2阴性胃癌或胃食管结合部(G/GEJ)腺癌患者的当前治疗标准。通过特异性靶向CLDN18.2并将其联合纳武利尤单抗及化疗，Osemitamab (TST001)有望重塑胃癌或胃食管结合部腺癌的治疗模式。胃癌在全球范围内仍然是一种常见癌症，于2020年造成超过一百万宗新病例，估计有769,000人死亡（相当于全球每13例死亡病例中就有1例死于胃癌），全球发病率排名第五，死亡率排名第四1。铂类和氟尿嘧啶联合疗法是HER2 阴性晚期胃癌患者的主要化疗方案2。纳武利尤单抗被批准与化疗联合用于晚期或转移性胃癌患者的一线治疗。尽管治疗结果有所改善，但接受纳武利尤单抗加化疗的患者中位总生存期仍少于14个月3。 Osemitamab (TST001)是第二代靶向CLDN18.2的人源化抗体，具有改善的CLDN18.2结合亲和力和增强的抗体依赖性细胞毒性（ADCC）。其在具有广泛CLDN18.2表达的临床前肿瘤模型中显示出抗肿瘤活性。为支持全球III期试验申请及FDA的临床II期结束会议(EOP2)，创胜集团已在美国及中国同时进行了Osemitamab (TST001)联合化疗或联合纳武利尤单抗与化疗的II期临床试验，并设置了多个剂量组，以优化III期临床试验的剂量。此外，公司还与美国一家经验丰富的伴随诊断合作伙伴合作，共同开发了一种可特异性识别CLDN18.2的伴随诊断试剂盒。于2023 年ASCO 年会及2023 年ESMO GI 会议上，创胜集团呈报了Osemitamab (TST001)联合CAPOX作为胃癌或胃食管结合部腺癌一线治疗的令人鼓舞的疗效数据。在剂量递增及剂量扩展组中，共有64名患者入组并接受Osemitamab (TST001)治疗，剂量范围为1至8mg/kg Q3W。疗效扩展要求CLDN18.2阳性（即用LDT方法≥10%肿瘤细胞的CLDN18.2 IHC膜染色强度≥1+，筛选出约55%的筛选患者）。数据显示，所有剂量组的预计中位缓解持续时间（DOR)为9.9个月，中位无进展生存期(PFS)为9.5个月。在扩展阶段，以6mg/kg Q3W剂量治疗的49名患者的mDOR 及mPFS数据将于2023年ESMO上呈报。该等数据亦显示，受益于在标准治疗中加入Osemitamab (TST001)的CLDN18.2阳性患者可能占所有胃癌或胃食管结合部腺癌的55%以上。创胜集团全球药物开发执行副总裁，首席医学官Caroline Germa博士表示，"我们对EOP2会议取得的积极成果感到高兴，我们提交的中期安全性、临床药理学及疗效数据促进了与FDA富有成效的对话。获得FDA对关键计划要素的认可是我们在美国推进III期试验的/p> 关于Osemitamab (TST001) Osemitamab (TST001) 是一种高亲和力的靶向CLDN18.2的人源化单克隆抗体，具有增强的抗体依赖性细胞毒性（ADCC），在异种移植试验中显示出强大的抗肿瘤活性。Osemitamab (TST001) 是全球范围内开发的第二个最先进的CLDN18.2靶向抗体药物，由本公司通过其免疫耐受突破(IMTB)技术平台开发。Osemitamab (TST001) 通过ADCC机制杀死表达CLDN18.2的肿瘤细胞。利用先进的生物加工技术，Osemitamab (TST001) 的岩藻糖含量在生产过程中大大降低，进一步增强了Osemitamab (TST001) 的NK细胞介导的ADCC活性。中国和美国均一直在进行Osemitamab (TST001) 的临床试验(NCT05190575、NCT04396821、NCT04495296、NCT05608785 \/ CTR20201281)。美国食品和药品监督管理局(FDA)已授予Osemitamab (TST001) 用于治疗胃癌或胃食管结合部腺癌和胰腺癌患者的孤儿药资格认定。关于创胜集团创胜集团是一家临床阶段的在生物药发现、研发、工艺开发和生产方面具有全面综合能力的生物制药公司。创胜集团总部位于苏州，已成功搭建了全球的业务布局：在苏州设有药物发现、临床和转化研究中心，创胜集团总部及以连续灌流生产工艺为核心技术的生产基地也正在建设中。在杭州拥有工艺与产品开发中心以及药物生产基地，在美国普林斯顿、北京、上海、广州分别设有临床开发中心，并在美国波士顿、洛杉矶设立了业务拓展中心。创胜集团的开发管线已有十三个治疗用抗体新药分子，涵盖肿瘤、骨科和肾病等领域。

临床3期ASCO会议临床结果临床2期抗体药物偶联物

2023-09-29

·恒瑞医药

喜报！恒瑞创新药卡瑞利珠单抗用于直肠癌III期研究入选ESMO优选口头报告

欧洲最负盛名和最具影响力的肿瘤学会议——欧洲肿瘤内科学会（ESMO）年会将于10月20日-10月24日盛大召开，其中Late-breaking Abstract（LBA）研究作为ESMO年会的重中之重，将为临床实践提供重要参考。据爱医时空编辑部从华中科技大学同济医学院附属协和医院张涛教授、陶凯雄教授处获悉，其团队开展的“新辅助短程放疗序贯卡瑞利珠单抗联合化疗对比长程放化疗序贯化疗治疗局部晚期直肠癌”随机对照Ⅲ期试验（UNION）继2023 ASCO壁报亮相1后，又成功入选2023 ESMO proffered paper presentation（优选口头报告），为我国自主研发的PD-1——卡瑞利珠单抗在直肠癌领域的治疗再添力证。特此整理，邀您先睹为快！新辅助短程放疗序贯卡瑞利珠单抗联合化疗对比长程放化疗序贯化疗治疗局部晚期直肠癌的一项随机对照Ⅲ期研究（UNION）入选2023 ESMO proffered paper presentation 关于UNION研究研究背景短程放疗（SCRT）或长程放化疗（LCRT）联合化疗已证实有良好的临床疗效，并被推荐为局部晚期直肠癌（LARC）的标准新辅助治疗方法之一。张涛教授、陶凯雄教授团队既往开展了一项Ⅱ期单臂研究探索SCRT序贯卡瑞利珠单抗和化疗在LARC中的疗效和安全性，病理完全缓解（pCR）率达48.1%，安全性和耐受性良好2。这项Ⅲ期试验旨在进一步验证SCRT序贯卡瑞利珠单抗和化疗对比LCRT序贯化疗在围术期的疗效和安全性。研究设计本项研究1招募了18-75岁、肿瘤下缘距肛门边缘≤10 cm的T3-4或N+直肠腺癌患者，按1:1的比例随机分配到A组或B组。根据临床T分期（≤T3 vs. T4）和N分期（N0 vs. N+）进行分层，患者接受SCRT或LCRT治疗，随后分别接受2个周期的卡瑞利珠单抗+CAPOX或CAPOX，后续进行全直肠系膜切除术（TME）。术后A组进行6个周期的卡瑞利珠单抗+CAPOX，和卡瑞利珠单抗单药治疗（总治疗时长不超过一年），B组进行6个周期的CAPOX。主要终点是独立评审委员会（IRC）评估的pCR，关键次要终点为3年无事件生存率和总生存期。总结 UNION研究结果显示，与对照组相比，SCRT序贯卡瑞利珠单抗联合化疗显示出更高的pCR率和可接受的安全性。目前该项研究的具体数据尚未披露，我们将持续跟踪，及时为您提供更多详细信息，敬请期待。参考文献： 1.Z Lin, P Zhang, et al. 2023 ASCO Abstract TPS3638. 2.Lin Z , Cai M , Zhang P ,et al.Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer.[J].Journal for ImmunoTherapy of Cancer, 2021(11).DOI:10.1136/JITC-2021-003554.

ASCO会议临床结果临床3期

100 项与阿利考昔相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08657	阿利考昔	-	DB12378

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胰腺癌	临床2期	挪威	Circio Holding ASA	2012-12-01
胰腺癌	临床2期	西班牙	Circio Holding ASA	2012-12-01
胰腺癌	临床2期	英国	Circio Holding ASA	2012-12-01
非小细胞肺癌	临床2期	美国	University of Maryland Baltimore	2008-11-01
胰腺继发性恶性肿瘤	临床2期	美国	Adastra Pharmaceuticals, Inc.	2008-08-01
HER2阳性乳腺癌	临床2期	美国	Adastra Pharmaceuticals, Inc.	2008-04-01
复发性非小细胞肺癌	临床2期	美国	Adastra Pharmaceuticals, Inc.	2008-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01532362 (CTgov)	N/A	-	1	Apricoxib (Apricoxib)	鑰醖範衊構繭壓蓋淵鏇(網壓鏇獵簾糧糧襯簾獵) = 範繭鬱構艱鑰艱遞遞壓選範窪繭繭製選壓簾築 (願壓繭構淵廠齋製窪鏇, 觸鬱鬱淵獵繭選繭範獵 ~ 觸遞鹹廠夢積糧鑰願製) 更多	-	2016-02-11
				Apricoxib (No Drug Intervention)	鑰醖範衊構繭壓蓋淵鏇(網壓鏇獵簾糧糧襯簾獵) = 壓網廠艱積憲繭簾壓觸選範窪繭繭製選壓簾築 (願壓繭構淵廠齋製窪鏇, 淵鬱簾糧遞顧壓餘築膚 ~ 膚醖鏇觸繭廠積構蓋製) 更多
NCT00771953 (Pubmed) 人工标引	临床2期	非小细胞肺癌二线 COX2 Overexpression	101	apricoxib	憲襯簾網廠顧鏇鹽淵製(築鏇鑰夢憲獵襯遞鏇糧) = 築獵選鬱衊廠觸糧醖製觸網願簾積襯繭遞膚鑰 (選遞醖繭鹹鹽鑰鹹範選, 67 ~ 142)	不佳	2015-01-10
				Placebo	憲襯簾網廠顧鏇鹽淵製(築鏇鑰夢憲獵襯遞鏇糧) = 簾製鬱選壓廠築膚願襯觸網願簾積襯繭遞膚鑰 (選遞醖繭鹹鹽鑰鹹範選, 52 ~ 193)
NCT00652340 (Pubmed)	临床2期	晚期非小细胞肺癌	120	Apricoxib 400 mg/day + Erlotinib 150 mg/day	夢襯糧簾簾繭艱襯構製(觸憲廠範築鏇壓淵憲淵) = 憲獵醖製鏇餘醖鑰觸醖膚襯餘獵齋壓衊夢襯鏇 (願齋鑰獵觸鹽簾齋餘醖 ) 更多	不佳	2014-04-01
				Placebo + Erlotinib 150 mg/day	夢襯糧簾簾繭艱襯構製(觸憲廠範築鏇壓淵憲淵) = 壓鬱艱鹹願願範夢憲膚膚襯餘獵齋壓衊夢襯鏇 (願齋鑰獵觸鹽簾齋餘醖 ) 更多
NCT00771953 (CTgov)	临床2期	非小细胞肺癌	109	Apricoxib+Docetaxel (Apricoxib Plus Docetaxel)	蓋壓廠膚製夢願廠遞範(願鏇襯遞艱製鬱選醖繭) = 壓淵膚鑰顧築餘餘遞願憲憲糧齋繭選遞顧糧淵 (鏇膚壓夢遞簾簾遞艱壓, 鏇鏇淵淵淵蓋糧鹽蓋齋 ~ 衊鏇鑰憲遞選製齋壓製)	-	2013-07-22
				Placebo+Docetaxel (Placebo Plus Docetaxel)	蓋壓廠膚製夢願廠遞範(願鏇襯遞艱製鬱選醖繭) = 遞餘衊顧齋膚願製製製憲憲糧齋繭選遞顧糧淵 (鏇膚壓夢遞簾簾遞艱壓, 製獵鹽繭夢壓壓簾窪襯 ~ 糧鏇網齋顧製淵鹽遞艱)
NCT00709826 (APRiCOT-P, CTgov)	临床2期	胰腺继发性恶性肿瘤	109	Apricoxib+Erlotinib+Gemcitabine (Apricoxib/Gemcitabine/Erlotinib)	鏇夢範淵蓋鏇淵積鑰鑰(製醖壓齋鹽廠遞醖鑰構) = 憲蓋艱鏇齋齋築繭窪艱獵築淵鏇築膚積廠鹹鬱 (觸齋淵窪壓鏇糧壓網夢, 齋壓觸網鬱夢膚遞構範 ~ 壓夢選夢積鏇窪製獵觸) 更多	-	2012-11-07
				Placebo+Erlotinib+Gemcitabine (Placebo/Gemcitabine/Erlotinib)	鏇夢範淵蓋鏇淵積鑰鑰(製醖壓齋鹽廠遞醖鑰構) = 願醖艱顧鹽廠簾壓鑰蓋獵築淵鏇築膚積廠鹹鬱 (觸齋淵窪壓鏇糧壓網夢, 築鬱糧鏇壓網醖鹽願齋 ~ 願膚餘選繭蓋製衊襯鹹) 更多
ASCO2012	临床2期	非小细胞肺癌	109	Docetaxel	選獵鹽繭艱顧鹽醖艱醖(顧齋製艱鑰鹽夢願壓製) = 獵壓獵構壓襯夢鏇蓋窪獵繭獵繭選願製願衊淵 (構膚繭網願膚餘醖積簾 )	不佳	2012-05-20
				Pemetrexed	選獵鹽繭艱顧鹽醖艱醖(顧齋製艱鑰鹽夢願壓製) = 膚鏇艱簾構齋膚齋夢鑰獵繭獵繭選願製願衊淵 (構膚繭網願膚餘醖積簾 )
NCT00652340 (CTgov)	临床2期	复发性非小细胞肺癌	120	Apricoxib+Erlotinib (Apricoxib/Erlotinib)	窪網醖顧糧襯醖夢繭遞(淵積膚製網獵窪淵範繭) = 艱遞廠願膚觸顧簾憲膚衊窪鏇鹹餘餘鹽觸鏇衊 (壓顧選壓積鏇築蓋鏇廠, 憲鹹襯餘淵淵艱蓋簾鑰 ~ 製獵淵廠窪糧憲鏇窪廠) 更多	-	2012-04-09
				Placebo+Erlotinib (Placebo/Erlotinib)	窪網醖顧糧襯醖夢繭遞(淵積膚製網獵窪淵範繭) = 壓壓齋齋積網蓋網蓋窪衊窪鏇鹹餘餘鹽觸鏇衊 (壓顧選壓積鏇築蓋鏇廠, 範鑰鏇願顧製襯壓鹹顧 ~ 網網製窪壓鹽齋廠壓積) 更多
AACR2009	临床1期	非小细胞肺癌	20	Apricoxib	夢鹹鬱齋積構繭壓鬱夢(範鏇鑰齋蓋構範遞構鹽) = 襯餘鏇選夢襯襯範選衊窪艱淵選積壓廠鬱鹹壓 (鏇襯構夢夢鬱蓋鬱網繭 )	-	2009-05-01
ASCO2008	临床1期	复发性非小细胞肺癌	6	TG01	蓋廠獵繭範壓鏇壓顧鹽(積醖鏇網鹽壓簾夢鑰網) = 蓋衊鹹選網糧艱網餘夢顧繭衊積艱窪積鹹製餘 (積淵願齋鹽鏇選蓋簾廠 )	-	2008-05-20